Swiss Life Sciences Stock News

V-ZUG Holding (SWX:VZUG) opened H1 2026 with total revenue of CHF 271.2 million and basic EPS of CHF 0.25, set against trailing 12 month revenue of CHF 580.8 million and EPS of CHF 1.89 that frame the results in a broader earnings season context. The company has seen revenue move from CHF 307.6 million in H2 2024 to CHF 271.2 million in H1 2025 and CHF 296.3 million in H2 2025, while basic EPS over those periods came in at CHF 1.97, CHF 0.25 and CHF 0.81 respectively. This gives investors a...

Novartis CEO has outlined plans to scale the use of artificial intelligence across the company’s research and development operations. The focus is on using AI to shorten drug discovery timelines and support better clinical decision making. This shift points to a potential long term change in how Novartis approaches its core business of developing new medicines. For investors watching SWX:NOVN, the update on AI comes after a period of strong share price performance, with the stock at...

VAT Group (SWX:VACN) has just posted its H1 2026 scorecard, with trailing twelve month revenue at CHF 1,027.4 million and basic EPS at CHF 6.93, setting the backdrop for how investors will read the latest half year print. The company has seen revenue move from CHF 492.6 million in H2 2024 to CHF 557.9 million in H1 2025 and CHF 515.6 million in H2 2025, while basic EPS shifted from CHF 3.92 to CHF 3.52 and CHF 3.63 over the same periods. This set of results therefore lands against a track...

Lonza Group (SWX:LONN) opened H1 2026 with Total Revenue of CHF 3.4b and Basic EPS of CHF 8.14, alongside Net Income (excluding extra items) of CHF 568m, setting a clear marker for its latest results. The company has seen revenue move from CHF 3.1b and EPS of CHF 5.65 in H1 2025, and CHF 3.1b and EPS of CHF 4.61 in H1 2024, giving investors a concrete view of how the top and bottom lines have tracked over recent reporting periods. With trailing 12 month EPS of CHF 15.47 and net profit margins...

Cicor Technologies (SWX:CICN) has reported its H1 2026 results with trailing twelve month revenue of CHF 669.9 million and net income of CHF 16.2 million, giving investors a clear view of how the recent period fits into its broader earnings run rate. Over recent halves, the company has seen revenue move from CHF 249.5 million in H2 2024 to CHF 280.7 million in H1 2025 and CHF 335.8 million in H2 2025, while basic EPS shifted from CHF 3.52 in H2 2024 to CHF 1.93 in H1 2025 and CHF 1.93 in H2...

Julius Bär Gruppe (SWX:BAER) has reported H1 2026 revenue of CHF 2.3b and basic EPS of CHF 3.27, with net income excluding extra items at CHF 672.2m setting the tone for the latest update. The company has seen revenue shift from CHF 1.81b in H1 2025 to CHF 1.95b in H2 2025 and then to CHF 2.28b in H1 2026, while basic EPS moved from CHF 1.44 to CHF 2.28 and now CHF 3.27. This gives investors a clear read on how the income statement has evolved across the last three reporting halves. Overall,...

Logitech International (SWX:LOGN) is in focus after analysts highlighted its record of exceeding earnings estimates and raised expectations for higher revenue and earnings ahead of the quarter ending June 2026. See our latest analysis for Logitech International. At a share price of CHF85.34, Logitech International has seen a 5.51% 7 day share price return and a 13.39% 90 day share price return, while the 1 year total shareholder return is 12.41%. This suggests that momentum has been gradually...

Georg Fischer AG has released its half-year 2026 results, reporting sales of CHF 1,584 million, revenue of CHF 1,615 million and a net loss of CHF 77 million, compared with a profit a year earlier. The swing from net income to a loss, alongside earnings per share moving from profit to loss, marks a clear reversal in the company’s recent financial performance. We’ll now examine how this shift from profit to loss in the latest half-year results could influence Georg Fischer’s investment...

EFG International earnings event and why it matters EFG International (SWX:EFGN) has drawn investor attention after reporting half year 2026 net income of CHF 184.6 million, down from CHF 221.2 million a year earlier, a material update for assessing the stock. See our latest analysis for EFG International. EFG International's share price has risen 7.88% over the past month and 4.51% over the past quarter, yet is still down 8.96% year to date. Longer term total shareholder returns of 16.41%...

Sensirion Holding (SWX:SENS) has just expanded its product line with the SFM3505-300 series flow sensors, targeting applications such as mechanical ventilation and gas mixing, alongside a fresh evaluation kit for indoor air quality gas sensors. See our latest analysis for Sensirion Holding. The back to back product launches appear to have coincided with a sharp shift in sentiment, with Sensirion Holding’s share price up 7.65% over one day but down 10.48% over 30 days. The year to date share...

The European market has recently experienced volatility, with the pan-European STOXX Europe 600 Index ending a week of fluctuations broadly unchanged. Amidst this backdrop, investors are keenly analyzing corporate earnings and geopolitical tensions to identify opportunities. In such an environment, stocks that may be trading at a discount often attract attention due to their potential for value appreciation when market conditions stabilize.

Bossard Holding (SWX:BOSN) has reported solid headline numbers for H1 2026, with revenue at CHF 575.7 million and net income at CHF 53.4 million setting the tone for its latest update. The company’s revenue increased from CHF 546.7 million in H1 2025 to CHF 575.7 million in H1 2026, while net income rose from CHF 37.4 million to CHF 53.4 million over the same period. Trailing twelve month net income reached CHF 87.9 million on revenue of CHF 1.1 billion. For investors, the focus now is...

What Roche Holding’s FDA Priority Review Could Mean for Investors Roche Holding (SWX:ROP) is back in focus after the US Food and Drug Administration granted Priority Review to its supplemental Biologics License Application for Gazyva/Gazyvaro in primary membranous nephropathy. This review status, supported by phase III MAJESTY trial data showing superiority to tacrolimus in achieving complete remission, puts regulatory timing and potential label expansion for Roche Holding on investors’...

Last week, you might have seen that DKSH Holding AG ( VTX:DKSH ) released its half-yearly result to the market. The...

Walliser Kantonalbank (SWX:WKBN) has reported its H1 2026 results with trailing 12 month revenue of CHF 276.4 million and net income of CHF 88.5 million, setting the stage against a backdrop where the net profit margin over the last year stood at 32% compared with 45% in the prior period. Over recent halves, the bank has seen revenue move from CHF 154.1 million in H2 2024 to CHF 135.7 million in H2 2025, alongside net income shifting from CHF 69.4 million to CHF 24.9 million. This leaves...

Swatch Group (SWX:UHR) has released its H1 2026 scorecard with trailing 12 month revenue of CHF6.4b and net income of CHF9m, set against a current share price of CHF186.35. The company has seen half year revenue move from CHF3.1b in H1 2025 to CHF3.2b in H2 2025, while net income shifted from CHF57m in H2 2024 to CHF3m and then CHF0m across the 2025 halves, leaving investors weighing weak recent profitability against analyst forecasts for 37.79% annual earnings growth. See our full analysis...

ALSO Holding (SWX:ALSN) has reported its H1 2026 numbers with revenue of about €7.1b and net income of €69.1m, while trailing twelve month revenue sits at roughly €14.7b with net income of €135.4m and EPS of €10.74. Over the past three reported half year periods, the company has seen revenue move from €5.9b in H1 2025 to €7.6b in H2 2025 and then to €7.1b in H1 2026, alongside net income shifting from €43.0m to €66.4m and then €69.1m, with EPS over the trailing twelve months at €10.74. For...

Novartis (SWX:NOVN) has posted fresh Q2 2026 numbers, with revenue at US$14.9 billion, basic EPS of US$1.71 and net income of US$3.3 billion, giving investors a clear read on how the business is currently earning its profits. Over recent quarters the company has seen revenue move between US$13.5 billion and US$14.9 billion, while basic EPS has ranged from US$1.26 to US$2.07. This provides a consistent earnings backdrop for assessing the latest release. With a trailing net profit margin of...

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) has just posted its H1 2026 numbers, with revenue of CHF2.4 billion and basic EPS of CHF840.60, while trailing 12 month EPS sits at CHF3,204.72 on revenue of CHF5.9 billion. Over recent periods the company has reported revenue of CHF2,369.5 million in H1 2025, CHF3,580.9 million in H2 2025, and CHF2,365.7 million in H1 2026, with EPS of CHF812.70, CHF2,368.83, and CHF840.60 over the same intervals. With earnings reported as up 8.2% over the past...

Schindler Holding (SWX:SCHN) has put fresh numbers on the table for Q2 2026, reporting revenue of CHF 2.7b, net income of CHF 252m and basic EPS of CHF 2.50, set against trailing twelve month EPS of CHF 9.63 on revenue of CHF 10.8b. Over recent quarters, the company has seen revenue move between CHF 2.59b and CHF 2.79b with EPS ranging from CHF 2.26 to CHF 2.50. Over the past year, earnings grew about 4.1% and net margin improved to 9.5% from 8.9%. Investors are now weighing these steadier...

CPH Group (SWX:CPHN) has posted its H1 2026 results with trailing twelve month revenue of CHF 333.8 million and basic EPS of CHF 3.42, against a backdrop of prior-period swings in both the top and bottom line. Over recent half-year periods, revenue has moved from CHF 146.4 million in H2 2024 to CHF 175.96 million in H1 2025 and CHF 158.11 million in H2 2025, while basic EPS shifted from CHF 2.23 to CHF 2.85 and then CHF 1.04. The latest release therefore sits in the middle of a mixed trend...

Belimo Holding (SWX:BEAN) has entered H1 2026 with solid recent numbers, having generated trailing twelve month revenue of CHF 1,120.8 million and basic EPS of CHF 14.77 off net income of CHF 181.6 million. The latest half year snapshots show H2 2025 revenue of CHF 559.3 million with EPS of CHF 6.54 and H1 2025 revenue of CHF 561.5 million with EPS of CHF 8.23. Over the past few reported periods, the company has seen revenue move from CHF 470.3 million in H2 2024 to CHF 561.5 million in H1...

Upcoming guidance call puts Partners Group Holding stock back in focus Partners Group Holding (SWX:PGHN) heads into its H1 2026 guidance and update call on 15 July after reporting record quarterly revenue of CHF 1.52b and net profit of CHF 682.5m. See our latest analysis for Partners Group Holding. Despite the record quarterly figures and the upcoming guidance call, Partners Group Holding’s share price is still under pressure, with a 90 day share price return down 27.17% and a 1 year total...

Earlier this month, Novartis received traditional FDA approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression, upgrading its earlier accelerated approval that was based on proteinuria reduction. The decision is grounded in two-year Phase III data showing Fabhalta’s first-in-class oral complement inhibition meaningfully slowed estimated glomerular filtration rate decline versus placebo, reinforcing...